ArticleStem cells international2021

Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin.

Tae Hyun Ban et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.